In the first video of the series, Jennifer A. Linehan, MD, provides an overview of LG-UTUC including risk factors, signs and symptoms, and diagnosis as well as factors to consider regarding disease progression, recurrence, and which patients might be candidates for resection.
In this companion article, Jennifer A. Linehan, MD, from the John Wayne Cancer Institute in Santa Monica, California, shares expert insight into factors affecting LG-UTUC diagnosis and treatment.
In the second video interview of the series, Sandip M. Prasad, MD, MPhil, reflects on the role of radical nephroureterectomy and endoscopic resection in patients with high- or low-grade UTUC and highlights clinical experience with kidney-sparing approaches including the use of mitomycin gel.
In this companion article, Sandip M. Prasad, MD, MPhil, from the Morristown Medical Center in New Jersey discusses the historic use of radical nephroureterectomy and provides an overview of his clinical experience using kidney-sparing approaches for LG UTUC.
In the third interview of the series, Sam S. Chang, MD, MBA, from the Vanderbilt University Medical Center shares key insights into the role of mitomycin gel as a kidney-sparing approach to the treatment of low-grade upper tract urothelial carcinoma.
In this companion article, Sam S. Chang, MD, MBA, offers his expert perspective on the use of mitomycin gel as a kidney-sparing approach to the management of low-grade upper tract urothelial carcinoma.
In the fourth interview of the series, Armine K. Smith, MD, from Sibley Memorial Hospital in Washington DC highlights considerations when discussing LG UTUC treatment options with patients including key points about response rates, adverse effects and long-term consequences, treatment availability, and insurance challenges.
In this companion article, Armine K. Smith, MD, reflects on the role of kidney-sparing approaches for LG UTUC and emphasizes the importance of patient-provider communication when making treatment decisions.
